全文获取类型
收费全文 | 1784823篇 |
免费 | 134301篇 |
国内免费 | 8744篇 |
专业分类
耳鼻咽喉 | 22720篇 |
儿科学 | 56774篇 |
妇产科学 | 47913篇 |
基础医学 | 253792篇 |
口腔科学 | 50693篇 |
临床医学 | 161745篇 |
内科学 | 348862篇 |
皮肤病学 | 39967篇 |
神经病学 | 137061篇 |
特种医学 | 67197篇 |
外国民族医学 | 300篇 |
外科学 | 267901篇 |
综合类 | 49543篇 |
现状与发展 | 23篇 |
一般理论 | 537篇 |
预防医学 | 130091篇 |
眼科学 | 42814篇 |
药学 | 132843篇 |
69篇 | |
中国医学 | 7978篇 |
肿瘤学 | 109045篇 |
出版年
2021年 | 16159篇 |
2019年 | 15962篇 |
2018年 | 22786篇 |
2017年 | 17561篇 |
2016年 | 18947篇 |
2015年 | 22133篇 |
2014年 | 30232篇 |
2013年 | 41649篇 |
2012年 | 58314篇 |
2011年 | 61459篇 |
2010年 | 36454篇 |
2009年 | 33702篇 |
2008年 | 55635篇 |
2007年 | 59111篇 |
2006年 | 59395篇 |
2005年 | 56529篇 |
2004年 | 53583篇 |
2003年 | 50986篇 |
2002年 | 48869篇 |
2001年 | 95738篇 |
2000年 | 97630篇 |
1999年 | 80789篇 |
1998年 | 21625篇 |
1997年 | 18828篇 |
1996年 | 18467篇 |
1995年 | 17685篇 |
1994年 | 16106篇 |
1993年 | 14688篇 |
1992年 | 59114篇 |
1991年 | 56746篇 |
1990年 | 54363篇 |
1989年 | 52034篇 |
1988年 | 47290篇 |
1987年 | 45964篇 |
1986年 | 43161篇 |
1985年 | 40783篇 |
1984年 | 29896篇 |
1983年 | 25330篇 |
1982年 | 14113篇 |
1979年 | 25819篇 |
1978年 | 17669篇 |
1977年 | 14989篇 |
1976年 | 13947篇 |
1975年 | 14653篇 |
1974年 | 17738篇 |
1973年 | 17055篇 |
1972年 | 15757篇 |
1971年 | 14531篇 |
1970年 | 13501篇 |
1969年 | 12584篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
11.
Yuxiang Ma Wenfeng Fang Hongyun Zhao Sai Praneeth Bathena Amol Tendolkar Jennifer Sheng Li Zhang 《The oncologist》2021,26(4):e549-e566
Lessons Learned
- The overall safety profiles of ipilimumab 3 mg/kg and 10 mg/kg administered every 3 weeks, were consistent between Chinese patients with solid tumors in the current study and patients from previous U.S. ipilimumab monotherapy studies. No new safety signals were identified.
- The mean systemic exposures to ipilimumab (assessed by first dose area under the curve during the dosing interval and maximum serum concentration) were numerically lower in the Chinese patient population than in U.S. patients for both 3 mg/kg and 10 mg/kg doses; however, the range of serum concentrations in the Chinese and U.S. populations overlapped (3 mg/kg and 10 mg/kg), suggesting that ipilimumab pharmacokinetics was ethnically insensitive in this study.
12.
Kara S. Tanaka MD Veronica R. Andaya BA Steven W. Thorpe MD Kenneth R. Gundle MD James B. Hayden MD Yee-Cheen Duong MD Raffi S. Avedian MD David G. Mohler MD Lee J. Morse MD Melissa N. Zimel MD Richard J. O'Donnell MD Andrew Fang MD Robert Lor Randall MD Tina H. Tran BS Christin New BA Rosanna L. Wustrack MD other members of Study Group FORCE 《Journal of surgical oncology》2023,127(1):148-158
13.
采用文献复习和实证研究经验的方法对《医疗质量管理办法》中涉及的医疗质量概念及相关问题进行探讨。《医疗质量管理办法》中的医疗质量的定义存在重大缺失,没有涉及医疗服务的结果,特别是患者安全。医疗质量的定义应与国际相关权威机构保持一致,应高度重视医疗服务的结果,特别是患者安全。 相似文献
14.
Comprehensive evidence regarding the treatment of non-anaemic iron deficiency in patients undergoing valvular heart surgery is lacking. This study aimed to investigate the association between non-anaemic iron deficiency and postoperative outcomes in these patients. We retrospectively analysed 321 patients of which 180 (56%) had iron deficiency (defined as serum ferritin < 100 ng.ml-1 or < 300 ng.ml-1 with transferrin saturation < 20%). While the iron-deficient group had lower pre-operative haemoglobin levels than the non-iron deficient group (median (IQR [range]) 134 (127–141 [120–172]) g.l-1, 143 (133–150 [120–179]) g.l-1, p = 0.001), there was no between-group difference in allogeneic red blood cell transfusion. Median (IQR [range]) days alive and out of hospital at postoperative day 90 was 1 day shorter in the iron-deficient group (80 (77–82 [9–85]) days vs. 81 (79–83 [0–85]) days, p = 0.026). In multivariable analysis, only cardiopulmonary bypass duration (p = 0.032) and intra-operative allogeneic red blood cell transfusion (p = 0.011) were significantly associated with reduced days alive and out of hospital at postoperative day 90. Iron deficiency did not exert any adverse influence on secondary outcomes except length of hospital stay. Our findings indicate that non-anaemic iron deficiency alone is not associated with adverse effects in patients undergoing valvular heart surgery when it does not translate into an increased risk of allogeneic transfusion. 相似文献
15.
Lei Yang You-Ling Shi Yan Ma Wei-Wei Ren Guang-Ming Pang Jiao Liu 《APMIS : acta pathologica, microbiologica, et immunologica Scandinavica》2022,130(1):43-52
Krüppel-like factor 16 (KLF16), a member of the Krüppel-like factor (KLF) family, has been extensively investigated in multiple cancer types. However, the role of KLF16 in oral squamous cell carcinoma (OSCC) remains unknown. Thus, we conducted this study to investigate its related mechanism. KLF16 expression in OSCC cell lines was quantified by western blotting. Then, OECM1 and OC3 cells were divided into Blank, siCtrl, siKLF16#1 and siKLF16#2 groups. Subsequently, cell proliferation was detected using 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide (MTT) assays, cell migration and invasion were detected with wound healing and Transwell assays, and cell cycle distribution and cell apoptosis were detected via flow cytometry. KLF16, p21, CDK4, Cyclin D1 and p-Rb expression was detected by western blotting. Finally, xenograft models were established in nude mice to observe the in vivo effects of KLF16 on OSCC. KLF16 protein expression was upregulated in OSCC cells. Compared to the cells in the Blank group, the OECM1 and OC3 cells in the siKLF16#1 group and siKLF16#2 group exhibited a sharp decrease in proliferation but a remarkable increase in apoptosis. Moreover, the proportion of cells in the G0/G1 phase notably increased and that in the S phase decreased, with evident decreases in cell invasion and migration. Moreover, KLF16, cyclin-dependent kinase 4 (CDK4), Cyclin D1 and p-Rb protein expression was upregulated, but p21 expression was downregulated. The mice in the siKLF16#1 and siKLF16#2 xenograft model groups exhibited slower tumour growth and smaller tumours with evident downregulation of Ki67 expression compared to the mice in the Blank group. KLF16 expression was upregulated in OSCC cells, and interfering with KLF16 led to cell cycle arrest, inhibited OSCC cell growth and promoted cell apoptosis. 相似文献
16.
17.
Clinical & Experimental Metastasis - 相似文献
18.
19.
Major depressive disorder is a serious and common neuropsychiatric disorder that affects more than 350 million people worldwide. Electroconvulsive therapy is the oldest and most effective treatment available for the treatment of severe major depressive disorder. Electroconvulsive therapy modifies structural network changes in patients with major depressive disorder and schizophrenia. And it can also affect neuroinflammatory responses and may have neuroprotective effects. Electroconvulsive therapy plays an irreplaceable role in the treatment of major depressive disorder. 相似文献
20.